Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 42 for:    LENALIDOMIDE AND Leukemia AND SLL

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01732861
Recruitment Status : Completed
First Posted : November 26, 2012
Last Update Posted : December 20, 2019
Sponsor:
Information provided by (Responsible Party):
Celgene

Tracking Information
First Submitted Date  ICMJE November 14, 2012
First Posted Date  ICMJE November 26, 2012
Last Update Posted Date December 20, 2019
Actual Study Start Date  ICMJE December 28, 2012
Actual Primary Completion Date January 23, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 19, 2012)
Adverse Events [ Time Frame: Up to 5 years ]
Number of participants with adverse events
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 21, 2019)
  • Percentage of Participants Who Have Received Some Form of Response [ Time Frame: Up to 2 years ]
    Response rate is defined as the percentage of participants who have achieved some form of response including: a Complete Response (CR), a CR with incomplete bone marrow recovery, a Nodular Partial Response (PR), a Nodal PR or a PR with lymphoctyosis) based on the International Workshop for Chronic Lymphocytic Leukemia and lymphoma guidelines (IWCLL).
  • PK-Cmax [ Time Frame: Up to 15 days ]
    Maximum observed plasma concentration
  • PK-Tmax [ Time Frame: Up to 15 days ]
    Time to maximum observed plasma concentration
  • PK-λz [ Time Frame: Up to 15 days ]
    Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear plasma concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration
  • PK-t1/2 [ Time Frame: Up to 15 days ]
    Estimate of the terminal elimination half-life in plasma
  • PK-AUC (0-t) [ Time Frame: Up to 15 days ]
    Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point
  • PK-AUC0-∞ [ Time Frame: Up to 15 days ]
    Area under the plasma concentration time curve from time zero extrapolated to infinity.
Original Secondary Outcome Measures  ICMJE
 (submitted: November 19, 2012)
  • Efficacy [ Time Frame: Up to 2 years ]
    Response rate on IWCLL (International Workshop for Chronic Lymphocytic Leukemia and lymphoma guidelines.
  • PK-Cmax [ Time Frame: Up to 15 days ]
    Maximum observed plasma concentration
  • PK-Tmax [ Time Frame: Up to 15 days ]
    Time to maximum observed plasma concentration
  • PK-λz [ Time Frame: Up to 15 days ]
    Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear plasma concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration
  • PK-t1/2 [ Time Frame: Up to 15 days ]
    Estimate of the terminal elimination half-life in plasma
  • PK-AUC (0-t) [ Time Frame: Up to 15 days ]
    Area under the plasma concentration-time curve from time zero to time t, where t is the last measurable time point
  • PK-AUC0-∞ [ Time Frame: Up to 15 days ]
    Area under the plasma concentration time curve from time zero extrapolated to infinity.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Official Title  ICMJE A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA
Brief Summary This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).
Detailed Description This dose finding study uses a 3 + 3 dose escalation and expansion design to establish the recommended Phase 2 dose. The starting dose is CC-292 375 mg twice daily and Lenalidomide 10 mg once daily. After review of the data for dose limiting toxicities (DLTs), the second dose level will be enrolled. Doses for this second cohort are CC-292 500 mg twice daily and lenalidomide 10 mg once daily. Additional doses of lenalidomide in combination with CC-292 may be evaluated to accurately determine the maximum tolerated dose. Once the maximum tolerated dose and/or optimal biologic effect has been ascertained, an expansion cohort of 24 subjects may be enrolled.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Leukemia Lymphocytic Chronic B-Cell
Intervention  ICMJE
  • Drug: CC-292
    CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
  • Drug: Lenalidomide
    Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
Study Arms  ICMJE Experimental: CC-292 + Lenalidomide
Interventions:
  • Drug: CC-292
  • Drug: Lenalidomide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 15, 2014)
20
Original Estimated Enrollment  ICMJE
 (submitted: November 19, 2012)
42
Actual Study Completion Date  ICMJE January 23, 2019
Actual Primary Completion Date January 23, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female subjects 18 years of age and older at the time of signing the informed consent document (ICD).
  • Body weight at least 50 kg.
  • Must have a documented diagnosis of CLL/SLL (International Workshop on Chronic Lymphocytic Leukemia IWCLL Guidelines - Hallek 2008) by investigator assessment.
  • Have failed at least 1 previous treatments for CLL/SLL, and have relapsed and/or refractory disease following last prior treatment defined as CLL/SLL that does not achieve at least a partial response (PR) to therapy or that progresses within 6 months of treatment.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 or less.
  • Life expectancy of at least 3 months from time of signing ICD.
  • Females of childbearing potential (FCBP) must have a negative medically supervised pregnancy test prior to starting study therapy and agree to ongoing pregnancy testing during and after end of study therapy; commit to continued abstinence from heterosexual intercourse or agree to use, comply with two effective methods of contraception without interruption, 28 days prior to starting study drug, during study therapy, and for 28 days after discontinuation of study therapy.
  • Male subjects must agree to use a latex condom during sexual contact with a FCBP even if they have had a vasectomy, throughout study drug therapy and dose interruption, and for 28 days after end of study therapy; agree to not donate semen or sperm during study drug therapy and for 28 days after end of study drug therapy.
  • All subjects must understand that lenalidomide could have a potential teratogenic risk, agree to abstain from donating blood with taking lenalidomide therapy and following discontinuation of study drug therapy; have an echocardiogram (ECG) or multigated acquisition (MUGA) scan of the heart demonstrating left ventricular ejection fraction (LVEF) at least 50% or the institution's lower limit of normal; have recovered from adverse, toxic effects of prior therapies to equal to or less than 1 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.03 except for alopecia and peripheral neuropathy.

Exclusion Criteria:

- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

  • Autologous stem cell transplant within 3 months prior to the time of signature on the ICD Informed Consent Document.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring parenteral antibiotics; uncontrolled diabetes mellitus; chronic symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarctions within 6 months prior to the time of signature on the ICD; clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia. Subjects with controlled atrial fibrillation that is asymptomatic are eligible.
  • Pregnant or lactating females.
  • Prior history of malignancies, unless the subject has been free of the disease for 5 years or more prior to the time of signature on the ICD. Exceptions to the 5 years or more time limit include history of basal cell carcinoma of the skin; squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; carcinoma in situ of the bladder; incidental histologic finding of prostate cancer (Tumor/Nodes/Metastasis [TNM] stage of T1a or T1b).
  • Known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).
  • Known seropositivity for hepatitis C virus (HCV); hepatitis B virus (HBV).
  • Subjects who are at a high risk for a thromboembolic event and are not willing/able to take venous thromboembolic event (VTE) prophylaxis.
  • Any of the following laboratory abnormalities:

    1. Absolute Neutrophil Count (ANC) ≤ 1,000 cells/mm3 (1.0 x 109/L)
    2. Platelet count ≤ 50,000/mm3 (50 x 109/L) unless secondary to bone marrow involvement by recent bone marrow aspiration and bone marrow biopsy
    3. Serum Aspartate Transaminase/Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) or Alanine Transaminase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) > 3.0 x upper limit of normal (ULN) or > 5.0 x ULN in cases of documented liver involvement
    4. Serum bilirubin > 1.5 x ULN or > 3.0 x ULN in cases of Gilbert's Syndrome and documented liver involvement by lymphoma;
    5. Calculated creatinine clearance using the Cockcroft-Gault formula (Cockcroft,1976)
    6. Corrected QT interval (QTc) prolongation (defined as a QTc > 450 msec for males and > 470 msec for females [Fridericia's correction]) or other clinically significant ECG abnormalities as assessed by the investigator.
  • Chemotherapy, radiotherapy, investigational anticancer therapy or major surgery within 28 days of Day 1 dosing.
  • Use of systemic corticosteroids in doses greater than prednisone equivalent to 20 mg/day within 3 weeks prior to study drug dosing.
  • Concomitant use of medicines known to cause QT prolongation or torsades de pointes.
  • Chronic use of H2 antagonists or proton pump inhibitors or their use within 7 days of first dose.
  • Gastrointestinal abnormalities including the inability to take oral medication, requiring intravenous alimentation, or prior surgical procedure affecting absorption.
  • Prior treatment with Btk (Bruton's tyrosine kinase) inhibitors.
  • Any live vaccinations within 3 weeks from first dose.
  • History of hypersensitivity to immunomodulatory drugs (IMiDs) (eg, lenalidomide, thalidomide, pomalidomide).
  • Disease transformation (ie, Richter's Syndrome [lymphomas] or prolymphocytic leukemia).
  • Patients with uncontrolled hyper or hypothyroidism.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   United States
Removed Location Countries Germany
 
Administrative Information
NCT Number  ICMJE NCT01732861
Other Study ID Numbers  ICMJE CC-292-CLL-001
2012-003766-41 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Celgene
Study Sponsor  ICMJE Celgene
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: David Liu, MD Celgene
PRS Account Celgene
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP